Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Shahid Beheshti University of Medical Sciences

Overview

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

bevacizumabDRUG

Injection of intravitreal bevacizumab

bevacizumab + triamcinolone acetonideDRUG

Injection of bevacizumab + triamcinolone acetonide

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cases of active neovascular AMD with visual acuity of 20/400- 20/40 Exclusion Criteria: * History of glaucoma or ocular hypertension * Disciform scar

Locations (1)

Hamid Ahmadieh, MD

Tehran, Tehran Province, Iran

Outcomes

Primary Outcomes

visual acuity

Secondary Outcomes

central macular thickness

leakage in fluorescein angiography

intraocular pressure

anterior chamber reaction

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.